TRCT
LABU icon

Tower Research Capital (TRC)’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Tower Research Capital (TRC)’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.13M Buy
42,919
+19,881
+86% +$3.26M 0.19% 97
2025
Q4 		$3.67M Sell
23,038
-35,133
-60% -$4.82M 0.09% 199
2025
Q3 		$5.45M Buy
58,171
+50,564
+665% +$3.57M 0.15% 113
2025
Q2 		$433K Sell
7,607
-7,498
-50% -$398K 0.01% 1101
2025
Q1 		$921K Sell
15,105
-11,943
-44% -$1.02M 0.03% 535
2024
Q4 		$2.43M Buy
27,048
+17,315
+178% +$2.04M 0.05% 314
2024
Q3 		$1.25M Sell
9,733
-4,541
-32% -$592K 0.03% 439
2024
Q2 		$1.62M Buy
14,274
+2,008
+16% +$215K 0.03% 518
2024
Q1 		$1.63M Sell
12,266
-16,813
-58% -$2.19M 0.04% 344
2023
Q4 		$3.55M Buy
29,079
+11,473
+65% +$878K 0.04% 342
2023
Q3 		$1.34M Buy
17,606
+17,570
+48,806% +$1.8M 0.04% 426
2023
Q2 		$4.23K Sell
36
-1,243
-97% -$155K ﹤0.01% 4972
2023
Q1 		$125K Buy
1,279
+1,243
+3,453% +$169K ﹤0.01% 1667
2022
Q4 		$5K Sell
36
-3,023
-99% -$422K ﹤0.01% 4878
2022
Q3 		$429K Buy
3,059
+2,737
+850% +$502K 0.01% 1266
2022
Q2 		$43K Buy
322
+239
+288% +$40.7K ﹤0.01% 3035
2022
Q1 		$26K Sell
83
-327
-80% -$123K ﹤0.01% 3287
2021
Q4 		$295K Buy
410
+380
+1,267% +$364K 0.01% 1488
2021
Q3 		$33K Sell
30
-2,004
-99% -$2.46M ﹤0.01% 3290
2021
Q2 		$3M Buy
2,034
+1,234
+154% +$1.71M 0.08% 188
2021
Q1 		$1.26M Sell
800
-360
-31% -$843K 0.02% 653
2020
Q4 		$2.33M Sell
1,160
-1,479
-56% -$2.36M 0.07% 182
2020
Q3 		$2.83M Buy
2,639
+2,604
+7,440% +$2.99M 0.03% 227
2020
Q2 		$41K Sell
35
-681
-95% -$591K ﹤0.01% 3204
2020
Q1 		$323K Sell
716
-2,264
-76% -$2.06M 0.02% 585
2019
Q4 		$3.43M Buy
2,980
+2,920
+4,867% +$2.62M 0.28% 32
2019
Q3 		$36K Sell
60
-1,725
-97% -$1.43M ﹤0.01% 2025
2019
Q2 		$1.79M Sell
1,785
-1,688
-49% -$1.63M 0.12% 124
2019
Q1 		$4.16M Sell
3,473
-1,225
-26% -$1.27M 0.25% 51
2018
Q4 		$3.09M Buy
4,698
+4,576
+3,751% +$4.8M 0.22% 93
2018
Q3 		$227K Sell
122
-1,876
-94% -$3.69M 0.02% 909
2018
Q2 		$3.79M Buy
+1,998
New +$3.52M 0.21% 86
2018
Q1 		– Sell
-1,707
Closed -$2.66M – 3573
2017
Q4 		$2.66M Sell
1,707
-185
-10% -$283K 0.34% 48
2017
Q3 		$3.23M Buy
1,892
+735
+64% +$1.02M 0.27% 49
2017
Q2 		$1.46M Buy
1,157
+1,156
+115,600% +$1.17M 0.17% 106
2017
Q1 		$1K Buy
+1
New +$891 ﹤0.01% 2806
2016
Q3 		– Sell
-7,627
Closed -$4.3M – 4057
2016
Q2 		$4.3M Sell
7,627
-1,482
-16% -$928K 0.41% 38
2016
Q1 		$5M Buy
9,109
+8,229
+935% +$5.2M 0.74% 20
2015
Q4 		$1.49M Buy
880
+701
+392% +$1.14M 0.24% 60
2015
Q3 		$233K Buy
+179
New +$546K 0.02% 259

Other funds holding LABU

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return
Belvedere Trading
Belvedere Trading Chicago, Illinois $84.4B AUM 52.68% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Tower Research Capital (TRC)'s LABU Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Direxion Daily S&P Biotech Bull 3X ETF (LABU) stake by 86% in Q1 2026, buying an estimated $3.26M and bringing the position to 42,919 shares worth $7.13M. The position accounts for 0.19% of the portfolio, ranked #97.

Tower Research Capital (TRC) first reported a position in LABU in Q3 2015 and has held it in 40 quarters since. 33 funds tracked by Wall St. Rank hold LABU as of Q1 2026.

  • Tower Research Capital (TRC) held 42,919 shares of Direxion Daily S&P Biotech Bull 3X ETF worth $7.13M as of Q1 2026.
  • Tower Research Capital (TRC) bought 19,881 Direxion Daily S&P Biotech Bull 3X ETF shares in Q1 2026, an estimated $3.26M.
  • Direxion Daily S&P Biotech Bull 3X ETF made up 0.19% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #97 holding.
  • Tower Research Capital (TRC) first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q3 2015 and has held it in 40 quarters since.
  • 33 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.